Helal DS et al. proposed an IHC algorithm using GATA3, KRT5, and p53 in patients, stratifying them into three subtypes: luminal with GATA3 expression, p53-WT subtype showing weak nuclear staining in less than 50% of tumour cells as a surrogate for a non-mutated TP53, and the basal subtype, which showed a significantly better response to NAC, while the p53-WT subtype was chemoresistant. The gene discussed is TP53; the disease is neoplasm.